Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Diabetic kidney disease is the most frequent cause of kidney failure, accounting for half of all cases worldwide. Moreover, deaths from diabetic kidney disease increased 106% between 1990 and 2013, with most attributed to cardiovascular disease. Recommended screening and monitoring for diabetic kidney disease are conducted in less than half of patients with diabetes. Standard-of-care treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker is correspondingly low. Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid antagonist are highly effective therapies to reduce kidney and cardiovascular risks in diabetic kidney disease. However, <20% of eligible patients are receiving these agents. Critical barriers are high out-of-pocket drug costs and low reimbursement rates. Data demonstrating clinical and cost-effectiveness of diabetic kidney disease care are needed to garner payer and health care system support. The pharmaceutical industry should collaborate on value-based care by increasing access through affordable drug prices. Additionally, multidisciplinary models and communication technologies tailored to individual health care systems are needed to support optimal diabetic kidney disease care. Community outreach efforts are also central to make care accessible and equitable. Finally, it is imperative that patient preferences and priorities shape implementation strategies. Access to care and implementation of breakthrough therapies for diabetic kidney disease can save millions of lives by preventing kidney failure, cardiovascular events, and premature death. Coalitions composed of patients, families, community groups, health care professionals, health care systems, federal agencies, and payers are essential to develop collaborative models that successfully address this major public health challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cost of new therapies is a barrier to implementation.40”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
New creatinine- and cystatin C-based equations to estimate GFR without race
Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102953 · Cited by 4,695
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Global trends in diabetes complications: a review of current evidence
Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E., & Gregg, E. W. (2019) · Diabetologia · doi:10.1007/s00125-018-4711-2 · Cited by 1,650
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationXie, Y., Bowe, B., Mokdad, A. H., Xian, H., Yan, Y., Li, T., Maddukuri, G., Tsai, C.-Y., Floyd, T., & Al-Aly, Z. (2018) · Kidney International · doi:10.1016/j.kint.2018.04.011 · Cited by 1,391
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
The KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Josephson, M. A. (2013) · Cited by 898
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
Self-citationTrends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017
Lawrence, J. M., Divers, J., Isom, S., Saydah, S., Imperatore, G., Pihoker, C., Marcovina, S. M., Mayer-Davis, E. J., Hamman, R. F., Dolan, L., et al. (2021) · JAMA · doi:10.1001/jama.2021.11165 · Cited by 619
Kim, K., Choi, J. S., Choi, E., Nieman, C. L., Joo, J. H., Lin, F. R., Gitlin, L. N., & Han, H.-R. (2016) · American Journal of Public Health · doi:10.2105/ajph.2015.302987 · Cited by 498
Delgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070988 · Cited by 423
Self-citation11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Tuttle, K. R., Alicic, R. Z., Duru, O. K., Jones, C. R., Daratha, K. B., Nicholas, S. B., McPherson, S. M., Neumiller, J. J., Bell, D. S., Mangione, C. M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18169 · Cited by 275
Self-citationKraft, S. A., Cho, M. K., Gillespie, K., Halley, M., Varsava, N., Ormond, K. E., Luft, H. S., Wilfond, B. S., & Lee, S. S.-J. (2018) · The American Journal of Bioethics · doi:10.1080/15265161.2018.1431322 · Cited by 271
Packham, D. K., Alves, T. P., Dwyer, J. P., Atkins, R., de Zeeuw, D., Cooper, M., Shahinfar, S., Lewis, J. B., & Lambers Heerspink, H. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.09.017 · Cited by 205
Cuffee, Y. L., Hargraves, J. L., Rosal, M., Briesacher, B. A., Schoenthaler, A., Person, S., Hullett, S., & Allison, J. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301554 · Cited by 188
Alfego, D., Ennis, J. L., Gillespie, B. S., Lewis, M. J., Montgomery, E., Ferrè, S., Vassalotti, J. A., & Letovsky, S. I. (2021) · Diabetes Care · doi:10.2337/dc21-0723 · Cited by 151
Goldenberg, R. M., Gilbert, J. D., Hramiak, I. M., Woo, V. C., & Zinman, B. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13811 · Cited by 114
Murphy, D. P., Drawz, P. E., & Foley, R. N. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018100971 · Cited by 106
Cardio-Renal-Metabolic Care Models: Toward Achieving Effective Interdisciplinary Care
Rangaswami, J., Tuttle, K., & Vaduganathan, M. (2020) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007264 · Cited by 80
Self-citationBullock, A., Burrows, N. R., Narva, A. S., Sheff, K., Hora, I., Lekiachvili, A., Cain, H., & Espey, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6601e1 · Cited by 64
Harris, S. T., Patorno, E., Zhuo, M., Kim, S. C., & Paik, J. M. (2021) · Diabetes Care · doi:10.2337/dc21-0529 · Cited by 59
McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14162 · Cited by 58
Reifsnider, O. S., Kansal, A. R., Wanner, C., Pfarr, E., Koitka-Weber, A., Brand, S. B., Stargardter, M., Wang, C., Kuti, E., & Ustyugova, A. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.014 · Cited by 52
Czeisler, M. É., Barrett, C. E., Siegel, K. R., Weaver, M. D., Czeisler, C. A., Rajaratnam, S. M. W., Howard, M. E., & Bullard, K. M. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7046a2 · Cited by 49
Time to eliminate health care disparities in the estimation of kidney function
Williams, W. W., Hogan, J. W., & Ingelfinger, J. R. (2021) · New England Journal of Medicine · doi:10.1056/nejme2114918 · Cited by 48
Cioana, M., Deng, J., Hou, M., Nadarajah, A., Qiu, Y., Chen, S. S. J., Rivas, A., Banfield, L., Chanchlani, R., Dart, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6069 · Cited by 47
Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.02.001 · Cited by 41
Self-citationMcEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14308 · Cited by 34
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius, F. C., Cherney, D. Z. I., Gee, P. O., Harris, R. C., Kliger, A. S., Tuttle, K. R., & Quaggin, S. E. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18641120 · Cited by 29
Self-citationImplications of specialist density for diabetes care in the United States.
Patel, R. B., Al Rifai, M., McEvoy, J. W., & Vaduganathan, M. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3796 · Cited by 28
Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease
Tuttle, K. R., Cherney, D. Z., & on behalf of the Diabetic Kidney Disease Task Force of the American Society of Nephrology (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07730719 · Cited by 24
Self-citationPreserving Kidney Function Instead of Replacing It
Kliger, A. S., Brosius, F. C., & on behalf of the Diabetic Kidney Disease Task Force of the American Society of Nephrology (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07820719 · Cited by 20
Self-citation
Research works printed but not linked: 4
- International Diabetes Federation : IDF Diabetes Atlas, 9th Ed., Brussels, Belgium, International Diabetes Federation, 2021 [Google Scholar]
- United States Renal Data System : 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2021 [Google Scholar]
- Johnson DC, O’Donnell J, Pothen M, Nguyen V, Smith T: Framework for specialty value transformation: Perspectives from a commercial payer. Health Affairs, August 27, 2021. Available at: https://www.healthaffairs.org/do/10.1377/forefront.20210825.518146/full/. Accessed February 18, 2022 · doi:10.1377/forefront.20210825.518146/full/
- The Medical Letter : Comparison Chart: Sodium glucose cotransporter 2 (SGLT2) inhibitors, May 17, 2021. Available at: https://secure.medicalletter.org/downloads/1611f_table.pdf. Accessed February 18, 2022 [DOI] [PubMed]
Cited by
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Self-citationNavaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248
Self-citationArtificial intelligence for visually impaired
Wang, J., Wang, S., & Zhang, Y. (2023) · Displays · doi:10.1016/j.displa.2023.102391 · Cited by 155
Mind the gap in kidney care: translating what we know into what we do
Luyckx, V. A., Tuttle, K. R., Abdellatif, D. A., Correa‐Rotter, R., Fung, W. W., Haris, A., Hsiao, L., Khalife, M., Kumaraswami, L. A., Loud, F. C., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.12.003 · Cited by 96
Self-citationOvercoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Nee, R. J., Yuan, C. M., Narva, A. S., Yan, G., & Norris, K. C. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac283 · Cited by 94
Metadata
- Authors
- Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., Cherney, D., Brosius, F. C., Argyropoulos, C., & Quaggin, S. E.
- Affiliations
- Northwestern University (US)
- Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
- Corresponding author
- Tuttle, Katherine R.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2022-07
- Volume
- 17
- Issue
- 7
- Pages
- 1092-1103
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC9269635
- OpenAlex
- W4281623679
- Cited by
- 87
- References
- 46
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 38 · 2023: 12 · 2022: 6
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, implementation barriers, breakthrough therapies, SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists, ACE inhibitors, angiotensin receptor blockers, drug costs, reimbursement, value-based care, cost-effectiveness, health care access, community outreach, patient preferences, multidisciplinary care model, cardiovascular risk, kidney failure prevention
- MeSH terms
- Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Renal Insufficiency, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.